Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.[2]

Cipla Limited
Traded asBSE: 500087
BSE SENSEX Constituent
CNX Nifty Constituent
FounderKhwaja Abdul Hamied
HeadquartersMumbai, Maharashtra, India
Area served
Key people
Y. K. Hamied, Chairman
Umang Vohra (CEO)
ProductsPharmaceuticals and diagnostics
RevenueUS$3.5 billion (2017-18)
US$1.5 billion (2017-18)
US$4 billion (2017-18)
Total assetsUS$5 billion (2017-18)
Total equityUS$2 billion (2017-18)
Number of employees
SubsidiariesInvagen Pharmaceuticals

As of 17 September 2014, its market capitalisation was 49,611.58 crore (US$7.2 billion), making it India's 42nd largest publicly traded company by market value.[3][4][5]

On 23 April 2019, Cipla appointed Dr. Raju Mistry as Global Chief People Officer.[6]


It was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935 in Mumbai.[7][8] The name of the Company was changed to 'Cipla Limited' on 20 July 1984.[8] In the year 1985, US FDA approved the company's bulk drug manufacturing facilities.[9] Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world.[10] In 1995, Cipla launched Deferiprone, the world’s first oral iron chelator.[7] In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).[11]

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited.[12][13] At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third biggest pharmaceutical company.[12] The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd.[14] In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company,[15] and in 2008 it changed its name to Cipla-Medpro.[16] I

Products and services

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products,[17] including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate.[1] They are the world's largest manufacturer of antiretroviral drugs[17][18]


Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.[19][20] Exports accounted for 48% 4,948 crore (equivalent to 63 billion or US$910 million in 2018) of its revenue for FY 2013-14.[21] Cipla spent INR 517 cr. (5.4% of revenue) in FY 2013-14 on R&D activities.[21] The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)).[1] During the FY 2013-14, the company incurred 1,285 crore (equivalent to 15 billion or US$220 million in 2018) on employee benefit expenses.[21]

Listings and shareholding

The equity shares of Cipla are listed on the Bombay Stock Exchange,[22] where it is a constituent of the BSE SENSEX index,[23] and the National Stock Exchange of India,[24] where it is a constituent of the CNX Nifty.[25] Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.[21]

As of 30 September 2014, the promoter group, Y. K. Hamied and his family held around 36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares.[26] LIC is the largest non-promoter shareholder with approx. 6.45% shareholding in the company by the end of September 2013.[27]

Shareholders (as on 31-March-2014)Shareholding[26]
Promoter Group36.80%
Foreign Institutional Investors (FII)23.32%
Individual shareholders19.00%
Insurance companies10.30
Private Corporate Bodies04.68%
Mutual Funds and UTI04.43%

Awards and recognitions

  • In 2012, Cipla received the Thomson Reuters India Innovation Award.[28]
  • Cipla won Dun & Bradstreet American Express Corporate Awards in 2006.[29]
  • In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.[30]
  • In 1980, Cipla won Chemexcil Award for Excellence for exports.[9]
  • In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list,[31] in a study conducted by BlueBytes,[32] a leading Media Analytics firm in association with TRA Research,[33] a brand insights organization (both a part of the Comniscient Group).


Emergency contraception

In August 2007, Cipla launched an emergency contraception drug "i-pill" sold over the counter,[34] which was controversial with regard to its being available without a prescription and the large amount of drug contained per dose.[35][36]

Generic drugs

In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries (ICI), which protested to the Indian government. The CEO of Cipla successfully lobbied the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs.[37] This change made propranolol and other patented drugs generic and led to criticism of both India's patent laws and Cipla.[38] India reinstated patents on drugs in 2005.[37]

See also


  1. "Business Responsibility Report 2013-14" (PDF). Cipla. 15 July 2014. Archived from the original (PDF) on 17 March 2015. Retrieved 17 September 2014.
  3. "Top Companies by Market Capitalisation". Money Control. 17 September 2014. Retrieved 17 September 2014.
  4. Cipla to sell MSD’s HIV drug in India | Business Line
  5. Cipla, Hetero to roll out biosimilar drug | Business Line
  6. "Cipla appoints Dr Raju Mistry as Global Chief People Officer". Medical Dialogues. 23 April 2019. Retrieved 23 April 2019.
  7. "About us - History". Cipla Limited. Archived from the original on 27 October 2015. Retrieved 3 November 2014.
  8. "Company History - Cipla Ltd". Economic Times. Retrieved 3 November 2013.
  9. "Company Profile - Cipla Limited". Retrieved 3 November 2013.
  10. "Interview with Yusuf Hamied". Creating Emerging Markets. Harvard Business School.
  11. "Indian drug company offers cheap AIDS drugs". USA Today. 19 June 2001. Retrieved 3 November 2013.
  12. Jawani, Lohit (16 July 2013). "Cipla completes acquisition of South Africa's Cipla Medpro". VC Circle. Archived from the original on 15 March 2016. Retrieved 8 September 2016.
  13. "Delists from JSE". Business Day Live. 2013. Retrieved 13 July 2013.
  14. "Enaleni Pharmaceuticals Limited Prospectus 2005". Morningstar. Retrieved 8 September 2016.
  15. Avafia, Tenu; Berger, Jonathan; Hartzenberg, Trudi (2006). "The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries" (PDF). WHO.
  16. Kahn, Tamar (10 September 2008). "South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro". All Africa.
  17. "cipla ltd (CIPLA:Natl India)". Business Week. Archived from the original on 6 November 2013. Retrieved 7 November 2013.
  18. "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India". PR Newswire. 8 August 2007. Retrieved 4 November 2013.
  19. "Corporate Information: At a Glance". Cipla. Retrieved 6 July 2019.
  20. "Cipla in the pink of health". Business Standard. 25 September 2013. Retrieved 5 November 2013.
  21. "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Archived from the original (PDF) on 22 January 2015. Retrieved 17 September 2014.
  22. "Cipla Limited". Retrieved 2 November 2013.
  23. "Scripwise Weightages in S&P BSE SENSEX". BSE India. Archived from the original on 1 December 2015. Retrieved 2 November 2013.
  24. "NTPC Limited". NSE India. Retrieved 2 November 2013.
  25. "Download List of CNX Nifty stocks (.csv)". NSE India. Retrieved 2 November 2013.
  26. "Shareholding pattern as on 30th September, 2013" (PDF). Cipla Limited. Retrieved 2 November 2013.
  27. "CIPLA - Shareholding belonging to the category : "Public and holding more than 1% of the Total No.of Shares"". 30 September 2013. Retrieved 4 November 2013.
  28. DBT, Cipla get Thomson Reuters India innovation awards
  29. "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Retrieved 3 November 2013.
  30. "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Retrieved 3 November 2013.
  31. "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". The Economic Times. 17 August 2016. Retrieved 6 July 2019.
  34. "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Retrieved 3 November 2013.
  35. "Cipla Launches i-pill". Financial Express. Retrieved 3 November 2013.
  36. "'i-pill' by Cipla draws criticism from experts". Financial Express. 27 October 2007. Retrieved 3 November 2013.
  37. "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
  38. "Indian Generic Drug Maker Targets Sad Americans". 3 January 2007. Retrieved 4 November 2013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.